Free Newsletter
Aspreva, Roche put CellCept on ice
Shares of Aspreva Pharmaceuticals slipped a bit this morning after the company and Roche announced that they would not be pushing ahead with a regulatory filing for CellCept, a new therapy for lupus nephritis. The therapy missed its late-stage primary endpoint--it was unable to demonstrate superiority to intravenous cyclophosphamide. There have been no new therapies approved for lupus in the U.S. in more than 40 years.
- check out the announcement
Related Articles:
Aspreva's CellCept fails late-stage superiority study. Report
Aspreva Pharmaceuticals drug fails Phase III trial. Report
CellCept wins orphan status. Report
More stories about Phase III lupus Roche Aspreva Pharmaceuticals Lupus Nephritis Orphan Status CellCept






Click here to get the FierceBiotech email newsletter for FREE!
Be the first to comment